News | June 04, 2007

Corgenix AspirinWorks Test Kit Cleared by FDA

June 4, 2007 — Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its AspirinWorks Test Kit, the Company's newest diagnostic product. More than one million Americans experience new or recurrent heart attacks each year. At risk individuals are eligible for aspirin therapy and should be tested for the presence or absence of the therapy's effect. The AspirinWorks Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion. "The 510(k) clearance of AspirinWorks is an enormous milestone for our company and important to the health of millions in the U.S. in addition to the rest of the world," said Douglass Simpson, Corgenix President and Chief Executive Officer. "We have significant expectations for this product due to the strong interest it has already attracted from the investment and health care communities. We believe that this product, in the intermediate-to long term, has the potential to generate worldwide revenues equal to or in excess of all of our other products combined." The AspirinWorks diagnostic test kit targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals. Simpson said the new test kit, already CE marked and available in Europe, will be sold through Corgenix U.S. sales force and distributed through its established network of laboratories. "Research has shown that up to 25 percent of individuals may be non-responsive to aspirin's benefits, and are more than three times more likely to die from heart disease," said Corgenix Clinical Affairs Director Gordon Ens. "This test can tell us if the aspirin fails to elicit an effect, thereby allowing physicians to individualize their patient's therapy." Unlike other platelet aggregation tests, which require freshly drawn blood that must be evaluated within at least 4 hours, the AspirinWorks test requires a urine sample that can easily be obtained in any doctor's office. Ens believes that any doctor should be able to order the AspirinWorks test now that FDA clearance has been received. "This can not come at a better time considering the recent American Heart Association (AHA) guidelines that suggest that women should consider an aspirin regimen to reduce their potential risk of heart attack and stroke," stated Ens. For more information visit: www.corgenix.com

Related Content

FDA Clears Abbott's High Sensitivity Troponin-I Blood Test
Technology | Blood Testing | October 09, 2019
Abbott recently announced that its Architect Stat High Sensitivity Troponin-I blood test has received clearance from...
Rapid Diagnosis Protocol for Chest Pain Does Not Improve Outcomes
News | Blood Testing | September 18, 2019
Discharge of patients with suspected acute coronary syndromes under a 0- and 1-hour high-sensitivity cardiac troponin T...
Validation Studies Confirm High Accuracy of Novel HART AI-Driven Blood Tests
News | Blood Testing | March 19, 2019
Prevencio Inc. announced data confirming the high accuracy of its artificial intelligence (AI)-driven, multiple-protein...
CoaguChek XS PT Test Strips Recalled for Inaccurately Reporting High INR
News | Blood Testing | December 28, 2018
Terrific Care LLC. / Medex Supply Dist Inc. initiated a nationwide recall on Dec. 19 of Roche CoaguChek test strips, as...
Abbott Point-of-Care Blood Test Speeds Heart Attack Diagnosis
News | Blood Testing | October 26, 2018
For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether...
New Noninvasive Blood Glucose Test as Effective as Finger Prick

Image courtesy of University of Missouri School of Medicine

News | Blood Testing | October 24, 2018
For those living with diabetes, monitoring blood glucose accurately is necessary to prevent diabetes-related...
Abbott Receives CE Mark for High Sensitive Troponin-I Test
News | Blood Testing | October 16, 2018
October 16, 2018 — Abbott announced that its High Sensitive Troponin-I...
AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient
News | Blood Testing | September 04, 2018
Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD)...
More Sensitive Blood Test Diagnoses Heart Attacks Faster
News | Blood Testing | August 06, 2018
August 6, 2018 — A new test to assess a whether or not someone is having a...
Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule